Back to results
US 2017/0247426 A1Published application
Modified glycoproteins
AssigneeMomenta Pharmaceuticals, Inc.
InventorsDorota A. Bulik, Carlos J. Bosques, Brian Edward Collins, Maurice Gaston Hains, Nathaniel J. Washburn, James Meador, Sean Smith, Naveen Bhatnagar
Life of this patent
Estimating the term…
Abstract
Sulfated glycoproteins, and methods of making and using such sulfated glycoproteins, are described.
Claims18
A preparation of abatacept, wherein at least 5% of the abatacept of the preparation comprises an Fc region comprising a sulfated glycan.
(canceled)
14-73. (canceled)
A method of modifying activity of a preparation of abatacept, the method comprising:
- providing a preparation of abatacept comprising an immunoglobulin Fc region comprising a glycan;
- and
- sulfating the glycan of at least 5% of the abatacept of the preparation,
- the abatacept comprising the sulfated glycan having a different Fc receptor affinity, Fc receptor specificity, complement activation activity, signaling activity, targeting activity, effector function, half-life, clearance, pro-inflammatory activity, anti-inflammatory activity, or transcytosis activity than a corresponding abatacept that does not comprise a sulfated glycan.
1 more element
75-91. (canceled)
A method of treating a subject with a therapeutic glycoprotein, the method comprising:
- providing a therapeutic glycoprotein comprising an immunoglobulin Fc region comprising a sulfated glycan;
- and
- administering the therapeutic glycoprotein comprising the sulfated glycan to a subject in need thereof,
- the therapeutic glycoprotein comprising the sulfated glycan having a level of activity different than a corresponding therapeutic glycoprotein not comprising a sulfated glycan, thereby treating the subject.
1 more element
93-129. (canceled)
Dependencies are inferred from the claim text.